David Johnson, MD
Internal Medicine · Owensboro, KYNPI 1215933247
Payments from drug & device makers
Across 112 payments — averaging $7029.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$343K
- AstraZeneca$276K
- Sage Therapeutics, LLC$77K
- Lexicon Pharmaceuticals, Inc.$51K
- Novartis$27K
- Swedish Orphan Biovitrum AB$10K
- plus $3K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 1 | $342,975 |
| AstraZeneca | 3 | $276,222 |
| Sage Therapeutics, LLC | 9 | $76,565 |
| Lexicon Pharmaceuticals, Inc. | 15 | $51,386 |
| Novartis | 8 | $26,562 |
| Swedish Orphan Biovitrum AB | 4 | $10,304 |
| Eli Lilly | 2 | $2,279 |
| Pfizer | 9 | $152 |
| Amarin Pharma, Inc. | 20 | $119 |
| Medtronic | 1 | $112 |
| Amgen | 8 | $111 |
| GSK | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $61 |
| Inspire Medical Systems, Inc. | 2 | $48 |
| Abbott | 2 | $43 |
| Ironshore Pharmaceuticals Inc. | 1 | $39 |
| Lilly USA, LLC | 2 | $31 |
| Exact Sciences | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Nevro Corp. | 1 | $25 |
| AbbVie | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Novo Nordisk | 1 | $12 |
| Endogastric Solutions, Inc | 1 | $10 |
How this compares
$787,280 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Owensboro
- Bernard BuchananOwensboro$224K
- Mahesh MoolaniOwensboro$14K
- Jeremy LuckettOwensboro$12K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.